Soluble amyloid-β oligomers (Aβo) are considered the most neurotoxic species of Aβ and key drivers of Alzheimer's disease (AD) pathogenesis. Selective targeting of Aβo offers a promising therapeutic strategy. We previously identified an amyloid-binding peptide (ABP) that binds Aβo and engages Aβ deposits in AD mouse and human brain tissue. To facilitate brain penetration, ABP was fused to the blood-brain barrier (BBB) transporter FC5 and an Fc fragment, generating BBB-permeable constructs (mouse FC5-mFc2a-ABP and humanized FC5-hFc-ABP, referred to as BBB-ABP). Previous in vivo studies demonstrated the ability of BBB-enabled ABP to engage and clear Aβ from the central nervous system.
Objective
This study aimed to evaluate the in vitro functionality of BBB-ABP and its ability to prevent Aβo-induced neurotoxicity and synaptic dysfunction.
Methods
Binding specificity was assessed using ELISA and western blot overlay assays. Functional assays were performed in SH-SY5Y cells and primary neurons to evaluate Aβo sequestration, protection against Aβo-induced toxicity, and effects on synaptic activity measured via multi-electrode arrays.
Results
BBB-ABP retained selective binding to Aβo and effectively prevented its interaction with neuronal proteins and its binding to dendritic spines in live primary neurons. BBB-ABP significantly reduced Aβo-induced toxicity in SH-SY5Y cells and primary neurons, including under conditions of NMDA-induced stress. Aβ exposure did not significantly alter spontaneous synaptic activity, precluding assessment of electrophysiological rescue by BBB-ABP.
Conclusions
These findings demonstrate that BBB-ABP maintains Aβo-selective binding and is capable of preventing the interaction of Aβo with neurons, thereby mitigating Aβo-induced toxicity in vitro, supporting its further development as a therapeutic candidate for AD.
KrafftGAJerecicJSiemersE, et al.ACU193: an immunotherapeutic poised to test the amyloid β oligomer hypothesis of Alzheimer’s Disease. Front Neurosci2022; 16: 848215.
2.
LiSSelkoeDJ. A mechanistic hypothesis for the impairment of synaptic plasticity by soluble Aβ oligomers from Alzheimer’s brain. J Neurochem2020; 154: 583–597.
3.
TolarMHeyJPowerA, et al.Neurotoxic soluble amyloid oligomers drive Alzheimer’s pathogenesis and represent a clinically validated target for slowing disease progression. Int J Mol Sci2021; 22: 6355.
4.
KaplanJMGibbsECouttsJA, et al.Relationship between efficacy and preferential targeting of soluble Aβ aggregates. Alzheimers Dement (N Y)2025; 11: e70184.
5.
SöderbergLJohannessonMGkanatsiouE, et al.Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities. Sci Rep2024; 14: 10868.
6.
ChakravarthyBMénardMBrownL, et al.A synthetic peptide corresponding to a region of the human pericentriolar material 1 (PCM-1) protein binds β-amyloid (Aβ1-42) oligomers. J Neurochem2013; 126: 415–424.
7.
ChakravarthyBItoSAtkinsonT, et al.Evidence that a synthetic amyloid-ß oligomer-binding peptide (ABP) targets amyloid-ß deposits in transgenic mouse brain and human Alzheimer’s disease brain. Biochem Biophys Res Commun2014; 445: 656–660.
8.
MuruganandamATanhaJNarangS, et al.Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J2002; 16: 240–242.
9.
AbulrobASprongHVan Bergen En HenegouwenP, et al.The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem2005; 95: 1201–1214.
10.
KangMSShinMOttoyJ, et al.Preclinical in vivo longitudinal assessment of KG207-M as a disease-modifying Alzheimer’s disease therapeutic. J Cereb Blood Flow Metab2022; 42: 788–801.
11.
LessardERennieKHaqqaniA, et al.Pharmacokinetics and pharmacodynamic effect of a blood-brain barrier-crossing fusion protein therapeutic for Alzheimer’s Disease in rat and dog. Pharm Res2022; 39: 1497–1507.
12.
FerreiraSTLourencoMVOliveiraMM, et al.Soluble amyloid-β oligomers as synaptotoxins leading to cognitive impairment in Alzheimer’s disease. Front Cell Neurosci2015; 9: 142972.
13.
VelascoPTHeffernMCSebollelaA, et al.Synapse-binding subpopulations of Aβ oligomers sensitive to peptide assembly blockers and scFv antibodies. ACS Chem Neurosci2012; 3: 972–981.
14.
SevignyJChiaoPBussièreT, et al.The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature2016; 537: 50–56.
15.
JezierskiABaumannEAylsworthA, et al.Electrophysiological- and neuropharmacological-based benchmarking of human induced pluripotent stem cell-derived and primary rodent neurons. Stem Cell Rev Rep2021; 18: 259–277.
16.
MosmannT. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods1983; 65: 55–63.
17.
MattsonMPChengBDavisD, et al.beta-Amyloid peptides destabilize calcium homeostasis and render human cortical neurons vulnerable to excitotoxicity. J Neurosci1992; 12: 376–389.
18.
KohJYangLLCotmanCW. β-Amyloid protein increases the vulnerability of cultured cortical neurons to excitotoxic damage. Brain Res1990; 533: 315–320.
19.
GrayCWPatelAJ. Neurodegeneration mediated by glutamate and β-amyloid peptide: a comparison and possible interaction. Brain Res1995; 691: 169–179.
20.
YanknerBADuffyLKKirschnerDA. Neurotrophic and neurotoxic effects of amyloid β protein: reversal by tachykinin neuropeptides. Science1990; 250: 279–282.
21.
CopaniAKohJCotmanCW. Beta-amyloid increases neuronal susceptibility to injury by glucose deprivation. Neuroreport1991; 2: 763–765.
22.
ShabalaLHowellsCWestAK, et al.Prolonged Aβ treatment leads to impairment in the ability of primary cortical neurons to maintain K+ and Ca2+homeostasis. Mol Neurodegener2010; 5: 30.
23.
SmithLMStrittmatterSM. Binding sites for amyloid-β oligomers and synaptic toxicity. Cold Spring Harb Perspect Med2017; 7: a024075.
24.
LacorPNBunielMCFurlowPW, et al.Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer’s disease. J Neurosci2007; 27: 796–807.
25.
LacorPNBunielMCChangL, et al.Synaptic targeting by Alzheimer’s-related amyloid β oligomers. J Neurosci2004; 24: 10191–10200.
26.
HayashiKIshikawaRYeLH, et al.Modulatory role of drebrin on the cytoskeleton within dendritic spines in the rat cerebral cortex. J Neurosci1996; 16: 7161–7170.
27.
PatnaikAZagrebelskyMKorteM, et al.Signaling via the p75 neurotrophin receptor facilitates amyloid-β-induced dendritic spine pathology. Sci Rep2020; 10: 13322.
28.
SinnenBLBowenABGibsonES, et al.Local and use-dependent effects of β-amyloid oligomers on NMDA receptor function revealed by optical quantal analysis. J Neurosci2016; 36: 11532–11543.
29.
Actor-EngelHSSchwartzSLCrosbyKC, et al.Precision mapping of amyloid-β binding reveals perisynaptic localization and spatially restricted plasticity deficits. eNeuro2021; 8: ENEURO.0416–21.2021.
30.
LordAGumucioAEnglundH, et al.An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer’s disease. Neurobiol Dis2009; 36: 425–434.
31.
RofoFBuijsJFalkR, et al.Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta. Transl Neurodegener2021; 10: 38.
32.
AdolfssonOPihlgrenMToniN, et al.An effector-reduced anti-β-amyloid (Aβ) antibody with unique Aβ binding properties promotes neuroprotection and glial engulfment of Aβ. J Neurosci2012; 32: 9677–9689.
33.
GibbsESilvermanJMZhaoB, et al.A rationally designed humanized antibody selective for amyloid beta oligomers in Alzheimer’s disease. Sci Rep2019; 9: 9870.
34.
SaiYChakravarthyBCallaghanD, et al.Dysregulation of insulin signaling in human AD brain and alleviation of Aβ-induced insulin resistance by amyloid-β binding peptide (ABP) in neural cells. J Neurol Disord2023; 11: 552.
35.
SallowaySChalkiasSBarkhofF, et al.Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. JAMA Neurol2022; 79: 13–21.
36.
HonigLSSabbaghMNvan DyckCH, et al.Updated safety results from phase 3 lecanemab study in early Alzheimer’s disease. Alzheimers Res Ther2024; 16: 105.
37.
SallowaySWojtowiczJVoyleN, et al.Amyloid-related imaging abnormalities (ARIA) in clinical trials of gantenerumab in early Alzheimer disease. JAMA Neurol2025; 82: 19–29.
38.
BatemanRJSmithJDonohueMC, et al.Two phase 3 trials of gantenerumab in early Alzheimer’s disease. N Engl J Med2023; 389: 1862–1876.
39.
SallowaySPainALeeE, et al.TRAILBLAZER-ALZ 4: a phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer’s disease. Alzheimers Dement2025; 21: e70293.
40.
ZimmerJAArdayfioPWangH, et al.Amyloid-related imaging abnormalities with donanemab in early symptomatic Alzheimer Disease: secondary analysis of the TRAILBLAZER-ALZ and ALZ 2 randomized clinical trials. JAMA Neurol2025; 82: 461–469.
41.
SchulteSGriesMChristmannA, et al.Using multielectrode arrays to investigate neurodegenerative effects of the amyloid-beta peptide. Bioelectron Med2021; 7: 15.
42.
O’ConnellAQuinlanLKwakowskyA. β-amyloid’s neurotoxic mechanisms as defined by in vitro microelectrode arrays: a review. Pharmacol Res2024; 209: 107436.
43.
VargheseKMolnarPDasM, et al.A new target for amyloid beta toxicity validated by standard and high-throughput electrophysiology. PLoS One2010; 5: e8643.
44.
AlhebshiAHGotohMSuzukiI. Thymoquinone protects cultured rat primary neurons against amyloid β-induced neurotoxicity. Biochem Biophys Res Commun2013; 433: 362–367.
45.
GaoFGaoKHeC, et al.Multi-site dynamic recording for Aβ oligomers-induced Alzheimer’s disease in vitro based on neuronal network chip. Biosens Bioelectron2019; 133: 183–191.
46.
LiuMChenCGaoK, et al.Neuronal network-based biomimetic chip for long-term detection of olfactory dysfunction model in early-stage Alzheimer’s disease. Biosens Bioelectron2022; 216: 114619.
47.
HendersonBWGreathouseKMRamdasR, et al.Pharmacologic inhibition of LIMK1 provides dendritic spine resilience against amyloid-β. Sci Signal2019; 12: eaaw9318.
48.
LeeSZemianekJSheaTB. Rapid, reversible impairment of synaptic signaling in cultured cortical neurons by exogenously-applied amyloid-β. J Alzheimers Dis2013; 35: 395–402.
49.
TaddeoMALeeSSheaTB. Synergistic inhibition of synaptic signaling in cortical cultures by subcytotoxic levels of oligomerized amyloid-β and iron: alleviation by zinc. J Alzheimers Dis2014; 41: 365–369.
50.
CharkhkarHMeyyappanSMatveevaE, et al.Amyloid beta modulation of neuronal network activity in vitro. Brain Res2015; 1629: 1–9.
51.
LiSHaydenEYGarciaVJ, et al.Activated bone marrow-derived macrophages eradicate Alzheimer’s-related Aβ42 oligomers and protect synapses. Front Immunol2020; 11: 505135.
52.
AminHNieusTLonardoniD, et al.High-resolution bioelectrical imaging of Aβ-induced network dysfunction on CMOS-MEAs for neurotoxicity and rescue studies. Sci Rep2017; 7: 2460.
53.
BaderBMJügeltKSchultzL, et al.Ginkgo biloba L. (Ginkgoaceae) leaf extract medications from different providers exhibit differential functional effects on mouse frontal cortex neuronal networks. Front Pharmacol2018; 9: 848.
54.
GörtzPOpatzJSieblerM, et al.Transient reduction of spontaneous neuronal network activity by sublethal amyloid β (1–42) peptide concentrations. J Neural Transm2009; 116: 351–355.
55.
LefebvreCVreulxACDumortierC, et al.Integration of microfluidic devices with microelectrode arrays to functionally assay amyloid-β-induced synaptotoxicity. ACS Biomater Sci Eng2024; 10: 1856–1868.
56.
GanbatDJeonJKLeeY, et al.Exploring the pathological effect of Aβ42 oligomers on neural networks in primary cortical neuron culture. Int J Mol Sci2023; 24: 6641.
57.
IversenLLMortishire-SmithRJPollackSJ, et al.The toxicity in vitro of beta-amyloid protein. Biochem J1995; 311: 1–16.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
